MnO 2 /carbon nanotube (CNT) composite was prepared by a solution process. In the obtained MnO 2 -CNT composite, MnO 2 particles were well-dispersed on CNTs. The specific capacitance of the MnO 2 -CNT composite in an aqueous electrolyte was higher than that of MnO 2 and CNT. All-solid-state electrochemical capacitors (ECs) were fabricated using the MnO 2 -CNT composite as a positive electrode, activated carbon powder as a negative electrode, and phosphosilicate gel as an electrolyte. The obtained all-solid-state ECs operated at the temperature range between -30⁰C and 100⁰C. The specific discharge capacitance and the rate ability of the capacitors were improved by elevating temperature. In addition, the fabricated all-solid-state ECs exhibited excellent cycle performance at the temperature range between -30⁰C and 100⁰C for 20,000 cycles.These results indicate that all-solid-state ECs using MnO 2 are promising energy storage devices with excellent stability and high reliability at the wide range of temperatures.

Zoledronic acid is an established agent used in the management of metastatic bone disease. The administration of zoledronic acid improves overall survival (OS) of lung cancer patients with bone metastases receiving chemotherapy. However, it is currently unknown whether zoledronic acid-induced fever is associated with OS. The purpose of this study was to examine the association between zoledronic acid-induced fever and prognosis in lung cancer patients with bone metastases. We retrospectively analyzed 98 lung cancer patients with bone metastases who had received zoledronic acid. The end point outcome measure was OS. Multivariate analyses were used to estimate the hazard ratio (HR) for OS due to fever after adjusting for covariates. In multivariate analysis, white blood cell (WBC) count, lactate dehydrogenase (LDH) level, fever, chemotherapy, and hypercalcemia were independent prognostic factors, with HRs of 2.834 for WBC count (<10 × 10³/μL vs. ≥10 × 10³/μL, p < 0.001), 3.044 for LDH level (<250 vs. ≥250 IU/L, p < 0.001), 0.603 for fever (<37.0 vs. ≥37.0°C, p = 0.039), 0.481 for chemotherapy (chemotherapy not administered vs. administered, p = 0.006), and 2.453 for hypercalcemia (<11.0 vs. ≥11.0 mg/dL, p = 0.001). Zoledronic acid-induced fever was the most important prognostic factor in this cohort of lung cancer patients with bone metastases.

No abstract

No abstract